Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02235311 · ClinicalTrials.gov registry record · NA

Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed

A NA study, sponsored by University of Missouri-Columbia.

Terminated
Registry status
NA
Development phase
3
Enrollment target

NCT02235311: Clinical Trial NA study, sponsored by University of Missouri-Columbia.

NCT02235311 is a NA study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02235311, a NA study, was terminated before completion, sponsored by University of Missouri-Columbia.

TERMINATED
Registry status
NA
Development phase
3 participants
Enrollment target

Study Summary

Despite recommendations from clinical practice guidelines to discharge patients from the hospital on once daily proton pump inhibitors after acute management of UGIB, clinical practice is to use twice daily proton pump inhibitor therapy. The objective of this study will be to assess whether or not once daily pantoprazole is non-inferior to twice daily pantoprazole in ulcer healing with a dose of once daily versus twice daily proton-pump inhibitor following an upper gastrointestinal bleed. Additionally, this study will observe for any potential difference in safety for once daily versus twice daily proton pump inhibitors.

Primary Outcome

as defined by follow-up endoscopy per gastroenterology service, 8 weeks after UGIB acute management

Interventions

  • DRUG Pantoprazole

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2014-10
Est. Completion 2015-08-17
Phase NA
University of Missouri-Columbia

291 total trials

Why NCT02235311 stopped before completion

NCT02235311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 1 intervention - of which Pantoprazole is the first listed.

NCT02235311 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02235311 about?

NCT02235311 is a clinical study titled "Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed". Despite recommendations from clinical practice guidelines to discharge patients from the hospital on once daily proton pump inhibitors after acute management of UGIB, clinical practice is to use twice daily proton pump inhibitor therapy. The objective of this study will be to assess whether or not o...

What is the current status of trial NCT02235311?

This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2014-10. Estimated completion is 2015-08-17.

What interventions are being tested in trial NCT02235311?

The interventions under investigation include: Pantoprazole (DRUG).

Who is sponsoring clinical trial NCT02235311?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02235311's enrollment target sits among peer trials

3 1996th of 2000 higher than 4 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02235311, the US trial registry maintained by the National Library of Medicine. NCT02235311 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.